Clinical trial
Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and…
NCT00359086 · Mirati Therapeutics Inc., Industry · Completed
Key facts
| NCT number | NCT00359086 |
|---|---|
| Title | Study of MGCD0103 Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma |
| Official title | A Phase II Study of MGCD0103 (MG-0103) Given Three Times Weekly in Patients With Relapsed and Refractory Lymphoma |
| Lead sponsor | Mirati Therapeutics Inc., Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma |
| Intervention type | Drug |
| Interventions | MGCD0103 |
| Enrollment | 74 |
| Start date | Aug 1, 2006 |
| Primary completion | Jan 1, 2012 |
| Completion | Jan 1, 2012 |
| First posted | Aug 1, 2006 |
| Last update posted | Jul 1, 2015 |
| Countries | Canada, United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: